Dr. Anne Marie Morse emphasizes that obstructive sleep apnea (OSA) extends beyond sleep disruption, leading to inflammation and increasing risks for stroke, dementia, and diabetes. She points out that many women are underdiagnosed, as subtle symptoms like irritability and attention issues are often overlooked. Early recognition of these symptoms is essential, especially given that millions live undiagnosed. Dr. Morse stresses the importance of listening to patients' stories to improve diagnosis.
Read More
Advancements in treatment options, including continuous positive airway pressure (CPAP) therapy, nerve stimulators, and innovative medications like tirzepatide, are encouraging. These developments offer new pathways to protect cognitive function and overall health. Additionally, Dr. Morse introduces her new book, "Communication in Healthcare: Charting the Course to Better Outcomes with Trust, Respect, and Teamwork," which aims to enhance collaboration between clinicians and patients. The book highlights how effective communication can lead to improved healthcare experiences and outcomes.
In discussing the mechanisms of cognitive decline associated with OSA, Dr. Morse notes the inadequacy of existing measurement paradigms and explains that OSA is fundamentally a brain issue, not a lung problem. It alters sleep patterns and increases stress responses, leading to neurodegenerative conditions. Cognitive dysfunction often begins with inattention, affecting daily functioning and decision-making.
Dr. Morse identifies key symptoms to watch for in patients, particularly those beyond classic daytime sleepiness. Many individuals seek help because they struggle with work performance or mood stabilization, yet often face diagnostic bias, especially women who may be dismissed as experiencing menopause-related issues.
Although it is unclear whether treating OSA can completely reverse cognitive impairment, evidence suggests that addressing OSA symptoms can rehabilitate daytime inattention and mood disturbances. Treatment variety includes CPAP, new medications like tirzepatide, and other approaches, enabling potential improvements in cognitive health.
The future of research in this area is promising, with ongoing developments expected in medications and therapies for OSA that affect cognitive and psychiatric outcomes. Dr. Morse is particularly optimistic about treatments targeting orexin pathways, which show potential for enhancing cognitive function.
In her book, Dr. Morse aims to facilitate better patient-clinician interactions and prepare patients to advocate for their health, highlighting the mutual roles in achieving optimal healthcare.